Dr Reddy's Flags Quality Concerns in Semaglutide Batches
Hyderabad-based pharmaceutical company Dr Reddy's Laboratories has reported that certain batches of semaglutide, a key ingredient used in blockbuster diabetes and obesity drugs, were found to be 'out of specification' during quality checks. The revelation was made in an exchange filing on July 9, 2026.
The company stated that the issue has impacted the supply of semaglutide, which is the active pharmaceutical ingredient (API) for drugs like Ozempic and Wegovy. Dr Reddy's is one of the few Indian manufacturers producing this API, and the quality lapse has raised concerns among investors and healthcare providers.
Impact on Supply and Stock Performance
Following the announcement, Dr Reddy's shares fell by 6% in intraday trading on the Bombay Stock Exchange (BSE). The stock closed at ₹4,250, down from the previous day's close of ₹4,521. The decline reflects market anxiety over potential revenue loss and regulatory scrutiny.
The company has initiated an investigation to determine the root cause of the deviation and is working to rectify the issue. In the filing, Dr Reddy's assured that it is taking corrective actions to ensure compliance with good manufacturing practices (GMP). However, it did not specify the number of batches affected or the financial impact of the supply disruption.
Industry Context and Regulatory Implications
Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and obesity. The global demand for these drugs has surged, leading to shortages and increased competition among generic manufacturers. Dr Reddy's had been scaling up production to capture market share, but this quality issue could delay its plans.
According to industry analysts, the 'out of specification' finding may trigger inspections by the US Food and Drug Administration (FDA) or other regulatory bodies, potentially leading to import alerts or sanctions. Dr Reddy's has a history of regulatory challenges, including a warning letter from the FDA for its Srikakulam plant in 2023.
Company Response and Future Outlook
In the exchange filing, Dr Reddy's stated, 'We are committed to maintaining the highest quality standards and are taking all necessary steps to address this issue.' The company did not provide a timeline for resuming normal supply.
Investors are advised to monitor updates from the company and regulatory agencies. The incident underscores the critical importance of quality control in pharmaceutical manufacturing, especially for high-demand drugs like semaglutide.
